B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients
ABSTRACTPatients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses pos...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2292376 |
| _version_ | 1827376125295198208 |
|---|---|
| author | Younes Bathish Neta Tuvia Elizabeth Eshel Tali Tal Lange Christiane Sigrid Eberhardt Michael Edelstein Kamal Abu-Jabal |
| author_facet | Younes Bathish Neta Tuvia Elizabeth Eshel Tali Tal Lange Christiane Sigrid Eberhardt Michael Edelstein Kamal Abu-Jabal |
| author_sort | Younes Bathish |
| collection | DOAJ |
| description | ABSTRACTPatients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses post 3rd and 4th dose of the BNT162b2 vaccine differed between PoD and controls. Non-infected PoD and controls vaccinated with BNT162b2 were recruited in Ziv Medical Center, Israel, between 2021 and 2022. Specimens were collected 1–2 months pre 3rd dose; 1–3 months post 3rd dose; 4–5 months post 3rd dose and 3–5 months post the 4th dose. Anti-SARS-CoV-2 spike (spike) specific antibodies, spike specific memory B cells, and spike specific CD154+ T cells as well as cytokines producing CD4+/CD8+ T cells were measured using standardized assays and compared between PoD and controls at each time point using Mann Whitney and Fisher’s exact tests. We recruited 22 PoD and 20 controls. Antibody levels in PoD were lower compared to controls pre 3rd dose but not post 3rd and 4th doses. Frequencies of spike specific memory B cell populations were similar between PoD and controls overall. Frequencies of spike specific T cells, including those producing IFNγ and TNFα, were not lower in PoD. B and T cell mediated immune response in PoD following a 3rd and a 4th dose of the BNT162b2 vaccine was not inferior to controls up to 5 months post vaccination. Our results suggest that standard BNT162b2 vaccination is suitable for this group. |
| first_indexed | 2024-03-08T12:04:26Z |
| format | Article |
| id | doaj.art-11e4972170684f7da931320abcf061b9 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-08T12:04:26Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-11e4972170684f7da931320abcf061b92024-01-23T09:20:04ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2023.2292376B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patientsYounes Bathish0Neta Tuvia1Elizabeth Eshel2Tali Tal Lange3Christiane Sigrid Eberhardt4Michael Edelstein5Kamal Abu-Jabal6Ziv Medcal Center, Safed, IsraelZiv Medcal Center, Safed, IsraelZiv Medcal Center, Safed, IsraelZiv Medcal Center, Safed, IsraelDepartment for Pediatrics, Gynecology and Obstetrics, Faculty of Medicine, University of Geneva, Geneva, SwitzerlandZiv Medcal Center, Safed, IsraelZiv Medcal Center, Safed, IsraelABSTRACTPatients on dialysis (PoD) are at high risk of severe morbidity and mortality from COVID-19. Characterizing long-term vaccine immune responses in these patients will help optimize vaccine schedule for PoD. This study aimed to determine whether long-term humoral and B and T cell-responses post 3rd and 4th dose of the BNT162b2 vaccine differed between PoD and controls. Non-infected PoD and controls vaccinated with BNT162b2 were recruited in Ziv Medical Center, Israel, between 2021 and 2022. Specimens were collected 1–2 months pre 3rd dose; 1–3 months post 3rd dose; 4–5 months post 3rd dose and 3–5 months post the 4th dose. Anti-SARS-CoV-2 spike (spike) specific antibodies, spike specific memory B cells, and spike specific CD154+ T cells as well as cytokines producing CD4+/CD8+ T cells were measured using standardized assays and compared between PoD and controls at each time point using Mann Whitney and Fisher’s exact tests. We recruited 22 PoD and 20 controls. Antibody levels in PoD were lower compared to controls pre 3rd dose but not post 3rd and 4th doses. Frequencies of spike specific memory B cell populations were similar between PoD and controls overall. Frequencies of spike specific T cells, including those producing IFNγ and TNFα, were not lower in PoD. B and T cell mediated immune response in PoD following a 3rd and a 4th dose of the BNT162b2 vaccine was not inferior to controls up to 5 months post vaccination. Our results suggest that standard BNT162b2 vaccination is suitable for this group.https://www.tandfonline.com/doi/10.1080/21645515.2023.2292376B cellsCOVID-19dialysisSARS-CoV-2T cellsvaccine |
| spellingShingle | Younes Bathish Neta Tuvia Elizabeth Eshel Tali Tal Lange Christiane Sigrid Eberhardt Michael Edelstein Kamal Abu-Jabal B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients Human Vaccines & Immunotherapeutics B cells COVID-19 dialysis SARS-CoV-2 T cells vaccine |
| title | B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients |
| title_full | B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients |
| title_fullStr | B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients |
| title_full_unstemmed | B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients |
| title_short | B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients |
| title_sort | b and t cell responses to the 3rd and 4th dose of the bnt162b2 vaccine in dialysis patients |
| topic | B cells COVID-19 dialysis SARS-CoV-2 T cells vaccine |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2023.2292376 |
| work_keys_str_mv | AT younesbathish bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients AT netatuvia bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients AT elizabetheshel bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients AT talitallange bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients AT christianesigrideberhardt bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients AT michaeledelstein bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients AT kamalabujabal bandtcellresponsestothe3rdand4thdoseofthebnt162b2vaccineindialysispatients |